<DOC>
	<DOCNO>NCT01439191</DOCNO>
	<brief_summary>The HER2 gene ( also know HER2/neu ErbB2 gene ) overexpressed 20-30 % human breast cancer lead particularly aggressive form disease . Trastuzumab , humanize anti-HER2/neu receptor monoclonal antibody , prove valuable treatment HER2-positive breast cancer patients.The combination trastuzumab chemotherapy show increase survival response rate , comparison trastuzumab alone . CMAB302 , biosimilar trastuzumab , develop Shanghai CP Guojian Pharmaceutical Co.Ltd . Efficacy safety CMAB302 single agent combination vinorelbine evaluate patient HER2-overexpressing metastatic breast cancer .</brief_summary>
	<brief_title>Study Cipterbin® , Used Alone With Vinorelbine Patients With HER2/Neu-overexpressed Metastatic Breast Cancer</brief_title>
	<detailed_description>The HER2 gene ( also know HER2/neu ErbB2 gene ) overexpressed 20-30 % human breast cancer lead particularly aggressive form disease . Trastuzumab , humanize anti-HER2/neu receptor monoclonal antibody , prove valuable treatment HER2-positive breast cancer patients.The combination trastuzumab chemotherapy show increase survival response rate , comparison trastuzumab alone . CMAB302 , biosimilar trastuzumab , develop Shanghai CP Guojian Pharmaceutical Co.Ltd . Previous Phase I study show CMAB302 well tolerate monotherapy pharmacokinetic data exhibit non-linear profile dose range 100 500 mg , similar trastuzumab . In study , efficacy safety CMAB302 single agent combination vinorelbine evaluate patient HER2-overexpressing metastatic breast cancer .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>pathologic diagnosis breast cancer HER2+ status define IHC3+ Staining situ hybridization positive least 1 measurable lesion per RECIST criterion Adequate bone marrow function ( absolute neutrophil count &gt; 1500/mm3 , platelet count &gt; 100.000/mm3 , hemoglobin &gt; 10gr/mm3 ) Adequate liver ( bilirubin &lt; 1.0 time upper limit normal SGOT/SGPT &lt; 2.5 time upper limit normal ) renal function ( creatinine &lt; 1.5mg/dl ) Adequate cardiac function ( LVEF &gt; 50 % ) . Normal electrocardiogram absence significant heart disease age 18 70y Karnofsky performance score ≥ 60 Life expectancy great 3 month Negative HCG pregnancy test premenopausal woman reproductive capacity woman less 12 month menopause . sign ICF prior exposure vinorelbine breast cancer prior exposure trastuzumab breast cancer Prior chemotherapy radiation therapy within last 4 week enrollment use investigational agent within last 4 week enrollment symptomatic , central nervous system metastases Hypersensitivity trial medication breastfeed pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2005</verification_date>
	<keyword>HER2-Overexpressed</keyword>
</DOC>